Last reviewed · How we verify
AXA1125
AXA1125 is a composition of amino acids and metabolites designed to restore metabolic balance and improve liver function in patients with metabolic dysfunction.
AXA1125 is a composition of amino acids and metabolites designed to restore metabolic balance and improve liver function in patients with metabolic dysfunction. Used for Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH).
At a glance
| Generic name | AXA1125 |
|---|---|
| Sponsor | Axcella Health, Inc |
| Drug class | Amino acid/metabolite composition |
| Modality | Small molecule |
| Therapeutic area | Hepatology/Metabolic Disease |
| Phase | Phase 2 |
Mechanism of action
AXA1125 works by modulating amino acid metabolism and restoring dysregulated metabolic pathways associated with liver disease and metabolic dysfunction. The therapeutic approach targets the underlying metabolic imbalances rather than a single molecular target, aiming to improve hepatic function and reduce fibrosis progression.
Approved indications
- Non-alcoholic fatty liver disease (NAFLD)
- Non-alcoholic steatohepatitis (NASH)
Common side effects
- Gastrointestinal disorders
- Nausea
- Abdominal discomfort
Key clinical trials
- Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection (PHASE2)
- Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis (PHASE2)
- Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |